USANA Health Sciences Financial Statements (USNA)
|
|
|
|
Report date
|
|
|
28.02.2023 |
31.12.2023 |
27.02.2024 |
12.03.2025 |
16.03.2026 |
|
05.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
998.6 |
921.0 |
921.0 |
854.5 |
925.3 |
|
925.9 |
|
Operating Income, bln rub |
|
|
107.6 |
93.1 |
93.1 |
66.3 |
50.9 |
|
49.1 |
|
EBITDA, bln rub |
? |
|
130.2 |
93.1 |
123.1 |
98.9 |
82.1 |
|
68.6 |
|
Net profit, bln rub |
? |
|
69.4 |
63.8 |
63.8 |
42.0 |
10.8 |
|
8.87 |
|
|
OCF, bln rub |
? |
|
103.9 |
|
70.6 |
61.0 |
22.3 |
|
6.87 |
|
CAPEX, bln rub |
? |
|
10.4 |
|
14.5 |
10.1 |
13.8 |
|
11.0 |
|
FCF, bln rub |
? |
|
93.5 |
|
56.1 |
50.9 |
8.53 |
|
-4.15 |
|
Dividend payout, bln rub
|
|
|
0.000 |
|
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
|
|
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
683.7 |
651.2 |
638.5 |
612.4 |
673.5 |
|
601.8 |
|
Cost of production, bln rub |
|
|
207.3 |
176.7 |
189.4 |
175.8 |
200.9 |
|
215.6 |
|
R&D, bln rub |
|
|
11.6 |
0.000 |
11.4 |
11.6 |
0.000 |
|
0.000 |
|
Interest expenses, bln rub |
|
|
0.192 |
0.000 |
0.262 |
0.281 |
0.842 |
|
0.671 |
|
|
Assets, bln rub |
|
|
596.5 |
632.8 |
632.8 |
748.2 |
742.9 |
|
739.0 |
|
Net Assets, bln rub |
? |
|
434.5 |
497.2 |
497.2 |
532.1 |
533.1 |
|
543.6 |
|
Debt, bln rub |
|
|
13.8 |
0.786 |
13.2 |
39.2 |
14.0 |
|
14.0 |
|
Cash, bln rub |
|
|
288.4 |
330.4 |
330.4 |
181.8 |
158.4 |
|
162.8 |
|
Net debt, bln rub |
|
|
-274.6 |
-329.6 |
-317.2 |
-142.6 |
-144.4 |
|
-148.8 |
|
|
Ordinary share price, rub |
|
|
53.2 |
53.6 |
53.6 |
|
|
|
19.9 |
|
Number of ordinary shares, mln |
|
|
19.3 |
19.3 |
19.3 |
19.1 |
18.6 |
|
18.4 |
|
|
Market cap, bln rub |
|
|
1 024 |
1 037 |
1 032 |
0 |
0 |
|
366 |
|
EV, bln rub |
? |
|
750 |
707 |
715 |
-143 |
-144 |
|
217 |
|
Book value, bln rub |
|
|
385 |
480 |
450 |
236 |
262 |
|
277 |
|
|
EPS, rub |
? |
|
3.60 |
3.30 |
3.31 |
2.20 |
0.58 |
|
0.48 |
|
FCF/share, rub |
|
|
4.86 |
0.00 |
2.92 |
2.67 |
0.46 |
|
-0.23 |
|
BV/share, rub |
|
|
20.0 |
24.8 |
23.4 |
12.4 |
14.1 |
|
15.0 |
|
|
EBITDA margin, % |
? |
|
13.0% |
10.1% |
13.4% |
11.6% |
8.87% |
|
7.40% |
|
Net margin, % |
? |
|
6.94% |
6.93% |
6.93% |
4.92% |
1.16% |
|
0.96% |
|
FCF yield, % |
? |
|
9.13% |
0.00% |
5.44% |
|
|
|
-1.14% |
|
ROE, % |
? |
|
16.0% |
12.8% |
12.8% |
7.90% |
2.02% |
|
1.63% |
|
ROA, % |
? |
|
11.6% |
10.1% |
10.1% |
5.62% |
1.45% |
|
1.20% |
|
|
P/E |
? |
|
14.8 |
16.3 |
16.2 |
0.00 |
0.00 |
|
41.2 |
|
P/FCF |
|
|
11.0 |
|
18.4 |
0.00 |
0.00 |
|
-88.1 |
|
P/S |
? |
|
1.03 |
1.13 |
1.12 |
0.00 |
0.00 |
|
0.40 |
|
P/BV |
? |
|
2.66 |
2.16 |
2.29 |
0.00 |
0.00 |
|
1.32 |
|
EV/EBITDA |
? |
|
5.76 |
7.60 |
5.80 |
-1.44 |
-1.76 |
|
3.17 |
|
Debt/EBITDA |
|
|
-2.11 |
-3.54 |
-2.58 |
-1.44 |
-1.76 |
|
-2.17 |
|
|
R&D/CAPEX, % |
|
|
111.2% |
|
79.0% |
114.9% |
0.00% |
|
0 |
|
|
CAPEX/Revenue, % |
|
|
1.04% |
0.00% |
1.57% |
1.18% |
1.49% |
|
1.19% |
|
| USANA Health Sciences shareholders |
